BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/22/2021 | $15.00 | Buy | BTIG |
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 38% Revenue growth over third quarter 2023 and 22% Recurring revenue growth in twelve-month trailing average Worldwide procedure volumes increased 29% over third quarter of 2023 Installed system base grew 20% over third quarter of 2023 ORLANDO, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LENSAR®, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307 1963 (International). The conference ID is 8444582. To access the live webcast, please go t
10-Q - LENSAR, Inc. (0001320350) (Filer)
8-K - LENSAR, Inc. (0001320350) (Filer)
10-Q - LENSAR, Inc. (0001320350) (Filer)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
SC 13G/A - LENSAR, Inc. (0001320350) (Subject)
BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00
SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00
SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
4 - LENSAR, Inc. (0001320350) (Issuer)
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. To participate by telephone, please use this registration link. All participants must use the link to complete the online registration process in advance
ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of February 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $10.65 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest as
ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,650 shares of the Company's common stock. The options were granted as of January 2, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $8.69 per share, which is equal to the closing price of the Company's common stock on the grant date. The options vest